Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anterix (ATEX) EBT (2016 - 2025)

Anterix's EBT history spans 13 years, with the latest figure at -$8.7 million for Q4 2025.

  • For Q4 2025, EBT fell 215.74% year-over-year to -$8.7 million; the TTM value through Dec 2025 reached $85.2 million, up 394.8%, while the annual FY2025 figure was -$9.5 million, 26.15% down from the prior year.
  • EBT reached -$8.7 million in Q4 2025 per ATEX's latest filing, down from $61.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $61.1 million in Q3 2025 to a low of -$14.3 million in Q2 2024.
  • Average EBT over 5 years is -$219200.0, with a median of -$8.2 million recorded in 2022.
  • Peak YoY movement for EBT: tumbled 561.22% in 2024, then skyrocketed 587.03% in 2025.
  • A 5-year view of EBT shows it stood at -$12.3 million in 2021, then soared by 36.52% to -$7.8 million in 2022, then soared by 121.33% to $1.7 million in 2023, then skyrocketed by 348.74% to $7.5 million in 2024, then plummeted by 215.74% to -$8.7 million in 2025.
  • Per Business Quant, the three most recent readings for ATEX's EBT are -$8.7 million (Q4 2025), $61.1 million (Q3 2025), and $22.9 million (Q2 2025).